Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLINICAL INVESTIGATOR FINANCIAL DISCLOSURE CHECK-OFF BOX PROPOSED BY HOPKINS' BLAKE; FDA BACKS TAILORING REGULATIONS TO ISOLATE MOST "PERNICIOUS" CASES

Executive Summary

Clinical investigators should disclose to FDA whether their financial involvement with a study sponsor exceeds a certain threshold but should not be required to make specific disclosures unless the agency so requests, Johns Hopkins Executive Vice Dean David Blake, PhD, suggested at an FDA Science Board meeting March 29.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel